MiMedx Planning U.S. Launch for Ambient Temperature Version of OrthoFlo
MiMedx is planning a U.S. launch for a next-generation lyophilized (freeze-dried) version of OrthoFlo, its amniotic fluid-based allograft for use in in orthopaedic and sports medicine applications.
This anticipated version of OrthoFlo can be stored at ambient temperature and has a five-year shelf life.
Date of product launch was not specified.
Source: MiMedx Group Inc.